Effects of incretin-based therapies on neuro-cardiovascular dynamic changes induced by high fat diet in rats

PLoS ONE

Volumn 11, Issue 2, 2016, Pages

  Marques Neto, Silvio Rodrigues ^a   Castiglione, Raquel Carvalho ^a   Pontes, Aiza ^a   Oliveira, Dahienne Ferreira ^b   Ferraz, Emanuelle Baptista ^b   Nascimento, José Hamilton Matheus ^b   Bouskela, Eliete ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; INCRETIN; LIRAGLUTIDE; SITAGLIPTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN MICROCIRCULATION; BRAIN MITOCHONDRION; CAPILLARY DENSITY; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; HEART LEFT VENTRICLE FUNCTION; HEART RATE VARIABILITY; INSULIN RESISTANCE; LIPID DIET; MALE; MEAN ARTERIAL PRESSURE; MITOCHONDRIAL PERMEABILITY; MITOCHONDRION SWELLING; NERVOUS SYSTEM; NONHUMAN; RAT; ANIMAL; BIOMETRY; BRAIN CIRCULATION; CALORIC INTAKE; CARDIAC MUSCLE; DRUG EFFECTS; HEART RATE; HEART VENTRICLE; METABOLISM; MICROCIRCULATION; WISTAR RAT;

ANIMALS; BIOMETRY; CARDIOVASCULAR SYSTEM; CEREBROVASCULAR CIRCULATION; DIET, HIGH-FAT; ENERGY INTAKE; GLUCOSE; HEART RATE; HEART VENTRICLES; INCRETINS; MALE; MICROCIRCULATION; MITOCHONDRIAL SWELLING; MYOCARDIUM; NERVOUS SYSTEM; RATS, WISTAR;

EID: 84959016669     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0148402     Document Type: Article

References (30)

1. Friedman JM. Causes and control of excess body fat. Nature. 2009; 459(7245):340-2. doi: 10.1038/ 459340a PMID: 19458707
2. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart Disease and Stroke Statistics-2014 Update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2014; 129(3):e28-e292. doi: 10.1161/01.cir.0000441139.02102. 80 PMID: 24352519
3. World Health Organization Outbreak media centre [Internet]. Fact sheet N° . 317 [March 2013]. Cardiovascular diseases. Available: http://www.who.int/mediacentre/factsheets/fs317/en/. Accessed 6 August 2014.
4. Torekov SS, Madsbad S, Holst JJ. Obesity-an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential. Obs Rev. 2011; 12, 593-601.
5. Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res. 2014; 114: 1788-1803. doi: 10.1161/CIRCRESAHA.114.301958 PMID: 24855202
6. Bonora E, Moghetti P, Zancanaro C, Cigolini M, Querena M, Cacciatori V, et al. Estimates of in vivo insulin action in man: comparison of insulin tolerance tests with euglycemic and hyperglycemic glucose clamp studies. J Clin Endocrinol Metab. 1989; 68: 374-378. PMID: 2645308
7. Marques-Neto SR, Silva AH, dos Santos MPC, Ferraz EF, Nascimento JHM. The blockade of angiotensin AT1 and aldosterone receptors protects rats from synthetic androgen-induced cardiac autonomic dysfunction. Acta Physiol (Oxf). 2013; 208:166-171.
8. Shih AY, Driscoll JD, Drew PJ, Nishimura N, Schaffer CB, Kleinfeld D. Two-photon microscopy as a tool to study blood flow and neurovascular coupling in the rodent brain. J Cereb Blood Flow Metab. 2012; 32:1277-1309. doi: 10.1038/jcbfm.2011.196 PMID: 22293983
9. Du H, Guo L, Fang F. Chen D, Sosunov AA, McKhann GM, et al. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer\'s disease. Nat Med. 2012; 14:1097-1105.
10. De Fronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin. 2008; 24: 2943-2952. doi: 10.1185/ 03007990802418851 PMID: 18786299
11. Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, et al; 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010; 375: 1447-1456. doi: 10.1016/S0140-6736(10)60307-8 PMID: 20417856
12. Burcelin R, Gourdy P, Dalle S. GLP-1-based strategies: A physiological analysis of differential mode of action. Physiology (Bethesda). 2014; 29:108-121.
13. Nakabayashi H, Nishizawa M, Nakagawa A, Takeda R, Niijima A. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am J Physiol Endocrinol Metab. 1996; 271:E808-E813.
14. Burcelin R. The gut-brain axis: a major glucoregulatory player. Diabetes Metab. 2010; 36 (Suppl 3): S54-S58. doi: 10.1016/S1262-3636(10)70468-7 PMID: 21211737
15. Li W, Prakash R, Chawla D, Du W, Didion SP, Filosa JA, et al. Early effects of high fat diet on neurovascular function and focal ischemic brain injury. Am J Physiol Regul Integr Comp Physiol. 2013; 304: R1001-R1008. doi: 10.1152/ajpregu.00523.2012 PMID: 23576615
16. Pannacciulli P, Le DS, Salbe A, Chen K, Reiman EM, Tataranni PA, et al. Postprandial glucagon-like peptide-1 (GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans. Neuroimage. 2007; 86:573-579.
17. Siesjo BK. Cerebral circulation and metabolism. J Neurosurg. 1984; 60:883-908. PMID: 6425463
18. Sivitz WI. Mitochondrial dysfunction in obesity and diabetes. US Endocrinol. 2010; 6:20-27.
19. Abel ED, Litwin SE, Sweeney G. Cardiac Remodeling in Obesity. Physiol Rev. 2008; 88:389-419. doi: 10.1152/physrev.00017.2007 PMID: 18391168
20. Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 2009; 58:975-983. doi: 10.2337/db08-1193 PMID: 19151200
21. Rowell LB. Human Cardiovascular Control. New York, NY: Oxford University Press; 1993:268.
22. De Boer MP, Meijer RI, Wijnstok NJ, Jonk AM, Houben AJ, Stehouwer CD, et al. Microvascular dysfunction: a potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension. Microcirculation. 2012; 19(1):5-18. doi: 10.1111/j.1549-8719.2011.00130.x PMID: 21883642
23. Serné EH, de Jongh RT, Eringa EC, IJzerman RG, Stehouwer CD. Microvascular dysfunction: a potential pathophysiological role in the metabolic syndrome. Hypertension. 2007; 50(1):204-11. PMID: 17470716
24. Maranhão PA, Kraemer-Aguiar LG, de Oliveira CL, Kuschnir MC, Vieira YR, Souza MG, et al. Brazil nuts intake improves lipid profile, oxidative stress and microvascular function in obese adolescents: a randomized controlled trial. Nutr Metab (Lond). 2011; 8(1):32.
25. van Raalte DH, Diamant M, Ouwens DM, Ijzerman RG, Linssen MM, Guigas B, et al. Glucocorticoid treatment impairs microvascular function in healthy men in association with its adverse effects on glucose metabolism and blood pressure: a randomised controlled trial. Diabetologia. 2013; 56(11):2383-91. doi: 10.1007/s00125-013-3016-8 PMID: 23933953
26. Kelley DE, He J, Menshikova EV, Ritov VB. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes. 2002; 51(10):2944-50. PMID: 12351431
27. Singer M, De Santis V, Vitale D, Jeffcoate W. Multiorgan failure is an adaptive, endocrine-mediated, metabolic response to overwhelming systemic inflammation. Lancet. 2004; 364(9433):545-8. PMID: 15302200
28. McBride HM, Neuspiel M, Wasiak S. Mitochondria: more than just a powerhouse. Curr Biol. 2006; 16 (14):R551-60. PMID: 16860735
29. Shah GN, Morofuji Y, Banks WA, Price TO. High glucose-induced mitochondrial respiration and reactive oxygen species in mouse cerebral pericytes is reversed by pharmacological inhibition of mitochondrial carbonic anhydrases: Implications for cerebral microvascular disease in diabetes. Biochem Biophys Res Commun. 2013; 440(2):354-8. doi: 10.1016/j.bbrc.2013.09.086 PMID: 24076121
30. Dan Dunn J, Alvarez LA, Zhang X, Soldati T. Reactive oxygen species and mitochondria: A nexus of cellular homeostasis. Redox Biol. 2015; 6:472-85. doi: 10.1016/j.redox.2015.09.005 PMID: 26432659